The Anti-inflammatory and Immunological Properties of SGLT-2 Inhibitors

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2023 Aug 3

PMID 37535237

Authors

G Bendotti

L Montefusco

I Pastore

E Lazzaroni

M E Lunati

P Fiorina

Affiliations

Soon will be listed here.

Abstract

Background: Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are antidiabetic oral drugs that act on proximal renal tubules promoting renal glucose excretion. Although SGLT-2i belong to the class of hypoglycemic agents, in the last years great interest has emerged in studying their pleiotropic effects, beyond their ability to lower glucose levels.

Purpose: In this review we are describing the anti-inflammatory and immunological properties of SGLT-2i; furthermore, we are addressing how the mechanisms associated with the aforementioned anti-inflammatory properties may contribute to the beneficial effects of SGLT-2i in diabetes.

Methods: A systematic search was undertaken for studies related the properties of SGLT-2i in reducing the inflammatory milieu of acute and chronic disease by acting on the immune system, independently by glycemia.

Results: Recently, some data described the anti-inflammatory and immunological properties of SGLT-2 in both pre-clinical and clinical studies. Numerous data confirmed the cardio- and -renal protective effects of SGLT-2i in patients with heart failure and kidney diseases, with or without diabetes.

Conclusions: SGLT-2i are promising drugs with anti-inflammatory and immunological properties. Despite the mechanism of action of SGLT-2i is not fully understood, these drugs demonstrated anti-inflammatory effects, which may help in keeping under control the variety of complications associated with diabetes.

Citing Articles

Sodium-glucose co-transporter inhibitors for APOL1 kidney disease: A call for studies.

Afsar B, Afsar R, Caliskan Y, Lentine K Int Urol Nephrol. 2025; .

PMID: 40038200 DOI: 10.1007/s11255-025-04443-z.

Effects of Anti-Diabetic Drugs on Erectile Dysfunction: A Systematic Review and Meta-Analysis.

Yang B, Cheng H, Hu Y, Chen Y, Xu Y, Huang W Diabetes Metab Syndr Obes. 2025; 18:467-478.

PMID: 39990178 PMC: 11844210. DOI: 10.2147/DMSO.S503216.

Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near.

Portalatin G, Hong-McAtee I, Burgner A, Gould E, Hunley T Front Pediatr. 2025; 13:1521425.

PMID: 39950157 PMC: 11821607. DOI: 10.3389/fped.2025.1521425.

Dapagliflozin improves diabetic kidney disease by inhibiting ferroptosis through β-hydroxybutyrate production.

Tian Y, Zhou C, Yan Q, Li Z, Chen D, Feng B Ren Fail. 2025; 47(1):2438857.

PMID: 39746795 PMC: 11703472. DOI: 10.1080/0886022X.2024.2438857.

New Insights into the Role of SGLT-2 Inhibitors in the Prevention of Dementia.

Hung C, Lu L Neurol Int. 2024; 16(6):1717-1730.

PMID: 39728750 PMC: 11676485. DOI: 10.3390/neurolint16060124.

References

Bendotti G, Montefusco L, Lunati M, Usuelli V, Pastore I, Lazzaroni E . The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists. Pharmacol Res. 2022; 182:106320. DOI: 10.1016/j.phrs.2022.106320. View

Lunati M, Cimino V, Gandolfi A, Trevisan M, Montefusco L, Pastore I . SGLT2-inhibitors are effective and safe in the elderly: The SOLD study. Pharmacol Res. 2022; 183:106396. DOI: 10.1016/j.phrs.2022.106396. View

Lazzaroni E, Lunati M, Montefusco L, Pastore I, Chebat E, Cimino V . Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study. Pharmacol Res. 2022; 183:106374. DOI: 10.1016/j.phrs.2022.106374. View

Francese R, Fiorina P . Immunological and regenerative properties of cord blood stem cells. Clin Immunol. 2010; 136(3):309-22. DOI: 10.1016/j.clim.2010.04.010. View

Williams M, Nadler J . Inflammatory mechanisms of diabetic complications. Curr Diab Rep. 2007; 7(3):242-8. DOI: 10.1007/s11892-007-0038-y. View

Tsalamandris S, Antonopoulos A, Oikonomou E, Papamikroulis G, Vogiatzi G, Papaioannou S . The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives. Eur Cardiol. 2019; 14(1):50-59. PMC: 6523054. DOI: 10.15420/ecr.2018.33.1. View

Feijoo-Bandin S, Aragon-Herrera A, Otero-Santiago M, Anido-Varela L, Morana-Fernandez S, Tarazon E . Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models. Int J Mol Sci. 2022; 23(10). PMC: 9144929. DOI: 10.3390/ijms23105634. View

Bray J, Foster-Davies H, Stephens J . A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress. Diabetes Res Clin Pract. 2020; 168:108368. DOI: 10.1016/j.diabres.2020.108368. View

Fiorentino T, Prioletta A, Zuo P, Folli F . Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Curr Pharm Des. 2013; 19(32):5695-703. DOI: 10.2174/1381612811319320005. View

10.

Folli F, Corradi D, Fanti P, Davalli A, Paez A, Giaccari A . The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach. Curr Diabetes Rev. 2011; 7(5):313-24. DOI: 10.2174/157339911797415585. View

11.

Cerami A, Vlassara H, Brownlee M . Protein glycosylation and the pathogenesis of atherosclerosis. Metabolism. 1985; 34(12 Suppl 1):37-42. DOI: 10.1016/s0026-0495(85)80008-1. View

12.

Brownlee M . Advanced protein glycosylation in diabetes and aging. Annu Rev Med. 1995; 46:223-34. DOI: 10.1146/annurev.med.46.1.223. View

13.

Folli F, Guzzi V, Perego L, Coletta D, Finzi G, Placidi C . Proteomics reveals novel oxidative and glycolytic mechanisms in type 1 diabetic patients' skin which are normalized by kidney-pancreas transplantation. PLoS One. 2010; 5(3):e9923. PMC: 2848014. DOI: 10.1371/journal.pone.0009923. View

14.

Cowie M, Fisher M . SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020; 17(12):761-772. DOI: 10.1038/s41569-020-0406-8. View

15.

Nasiri-Ansari N, Nikolopoulou C, Papoutsi K, Kyrou I, Mantzoros C, Kyriakopoulos G . Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE Mice by Activating Autophagy and Reducing ER Stress and Apoptosis. Int J Mol Sci. 2021; 22(2). PMC: 7829901. DOI: 10.3390/ijms22020818. View

16.

Diaz-Rodriguez E, Agra R, Fernandez A, Adrio B, Garcia-Caballero T, Gonzalez-Juanatey J . Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability. Cardiovasc Res. 2017; 114(2):336-346. DOI: 10.1093/cvr/cvx186. View

17.

Iacobellis G, Baroni M . Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat. J Endocrinol Invest. 2021; 45(3):489-495. DOI: 10.1007/s40618-021-01687-1. View

18.

Uthman L, Homayr A, Juni R, Spin E, Kerindongo R, Boomsma M . Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells. Cell Physiol Biochem. 2019; 53(5):865-886. DOI: 10.33594/000000178. View

19.

Sukhanov S, Higashi Y, Yoshida T, Mummidi S, Aroor A, Jeffrey Russell J . The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion. Cell Signal. 2020; 77:109825. PMC: 8118186. DOI: 10.1016/j.cellsig.2020.109825. View

20.

Rossing P, Inzucchi S, Vart P, Jongs N, Docherty K, Jhund P . Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes Endocrinol. 2021; 10(1):24-34. DOI: 10.1016/S2213-8587(21)00295-3. View